Project Details
| Short title | AP402-101 |
|---|---|
| Status | Finished |
| Effective start/end date | 14/02/25 → 16/12/25 |
CTU: A Phase 1/2, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP402 in HER2-Positive Patients with Locally or Advanced Solid Tumors
- Parsonson, Andrew (Primary Chief Investigator)
- Quinlan, Gabriel (Clinical Trial Unit Staff)
- TAIDI, Gina (Clinical Trial Unit Staff)
- Martin, Lewis (Clinical Trial Unit Staff)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Armstrong, Emilia (Clinical Trial Unit Staff)
- Garcia, Michelle (Clinical Trial Unit Staff)
Project: Research